IllnessCataract [primarily isolated], differential diagnosis
Summary
Comprehensive differential diagnostic panel for isolated Cataract containing 20 core candidate genes and altogether 137 curated genes according to the clinical signs
123,2 kb (Extended panel: incl. additional genes)
- EDTA-anticoagulated blood (3-5 ml)
NGS +
Gene panel
Selected genes
Name | Exon Length (bp) | OMIM-G | Referenz-Seq. | Heredity |
---|---|---|---|---|
BFSP1 | 1998 | NM_001195.5 | AD, AR | |
BFSP2 | 1248 | NM_003571.4 | AD | |
CHMP4B | 675 | NM_176812.5 | AD | |
CRYAA | 522 | NM_000394.4 | AD, AR | |
CRYBA1 | 648 | NM_005208.5 | AD | |
CRYBB1 | 759 | NM_001887.4 | AD, AR | |
CRYBB2 | 618 | NM_000496.3 | AD | |
CRYBB3 | 636 | NM_004076.5 | AD, AR | |
CRYGC | 525 | NM_020989.4 | AD | |
CRYGD | 525 | NM_006891.4 | AD | |
CRYGS | 537 | NM_017541.4 | AD | |
EPHA2 | 2931 | NM_004431.5 | AD | |
FOXE3 | 960 | NM_012186.3 | AD, AR | |
GCNT2 | 1203 | NM_001491.3 | AR, AD | |
GJA3 | 1308 | NM_021954.4 | AD | |
HSF4 | 1389 | NM_001538.4 | AD | |
MIP | 792 | NM_012064.4 | AD | |
PAX6 | 1269 | NM_000280.5 | AD | |
PITX3 | 909 | NM_005029.4 | AD | |
ABHD12 | 1197 | NM_001042472.3 | AR | |
AGK | 1269 | NM_018238.4 | AR | |
ALDH18A1 | 2388 | NM_002860.4 | AD, AR | |
ATAD3A | 1761 | NM_001170535.3 | AR | |
COL2A1 | 4464 | NM_001844.5 | AD | |
COL4A1 | 5010 | NM_001845.6 | AD | |
COL4A2 | 5139 | NM_001846.4 | AD | |
CRYAB | 528 | NM_001885.3 | AD, AR | |
CRYBA2 | 594 | NM_057093.2 | AD | |
CRYBA4 | 591 | NM_001886.3 | AD | |
CRYGB | 528 | NM_005210.4 | AD | |
CTDP1 | 2529 | NM_004715.5 | AR | |
CYP27A1 | 1596 | NM_000784.4 | AR | |
DHCR7 | 1428 | NM_001360.3 | AR | |
EIF2B2 | 1056 | NM_014239.4 | AR | |
ERCC2 | 2283 | NM_000400.4 | AR | |
ERCC3 | 2349 | NM_000122.2 | AR | |
EYA1 | 1779 | NM_000503.6 | AD | |
FAR1 | 1548 | NM_032228.6 | AD, AR | |
FTL | 528 | NM_000146.4 | AD | |
FYCO1 | 4437 | NM_024513.4 | AR | |
GALK1 | 1179 | NM_000154.2 | AR | |
GALT | 1140 | NM_000155.4 | AR | |
GJA8 | 1302 | NM_005267.5 | AD | |
GTF2H5 | 216 | NM_207118.3 | AR | |
LIM2 | 648 | NM_030657.4 | AR | |
LONP1 | 2688 | NM_001276479.2 | AR | |
LSS | 2303 | NM_001001438.3 | AR | |
MAFA | 1062 | NM_201589.4 | AD | |
NF2 | 1788 | NM_000268.4 | AD | |
NHS | 4425 | NM_001136024.4 | XL | |
OPA3 | 540 | NM_025136.4 | AD | |
PEX10 | 1041 | NM_153818.2 | AR | |
PEX11B | 780 | NM_003846.3 | AR | |
PEX16 | 1011 | NM_004813.4 | AR | |
PEX2 | 918 | NM_000318.3 | AR | |
PEX6 | 2943 | NM_000287.4 | AR | |
PEX7 | 972 | NM_000288.4 | AR | |
POLG | 3720 | NM_002693.3 | AD, AR | |
RAB3GAP2 | 4182 | NM_012414.4 | AR | |
RRAGA | 943 | NM_006570.5 | AD | |
SIL1 | 1386 | NM_022464.5 | AR | |
SIPA1L3 | 5366 | NM_015073.3 | AR | |
SLC16A12 | 1551 | NM_213606.4 | AD | |
SLC2A1 | 1479 |
| NM_006516.4 | AD |
SLC40A1 | 1716 | NM_014585.6 | AD | |
SRD5A3 | 957 | NM_024592.5 | AR | |
SREBF1 | 3534 | NM_001005291.3 | AD | |
TDRD7 | 3297 | NM_014290.3 | AR | |
TRPM3 | 768 | NM_001007470.3 | AD | |
UNC45B | 2790 | NM_001033576.2 | AD | |
VIM | 1401 | NM_003380.5 | AD | |
WFS1 | 2673 | NM_006005.3 | AD, AR |
Informations about the disease
High clinical + genetic heterogeneity, most frequently characterized by bilateral, symmetrical, non-progressive cataracts which present at birth or in early-childhood. Additional ocular manifestations (e.g. anterior segment dysgenesis, colobomas, nystagmus, microcornea, microphthalmia, myopia) may be associated, however other organs/systems are usually not affected
- Allelic: Adult i phenotype without cataract (GCNT2)
- Allelic: Alopecia-mental retardation syndrome 4 (LSS)
- Allelic: Angiopathy, hereditary, with nephropathy, aneurysms + muscle cramps (COL4A1)
- Allelic: Aniridia (PAX6)
- Allelic: Aortic aneurysm, familial thoracic 11, susceptibility to (FOXE3)
- Allelic: Ayme-Gripp syndrome (MAF)
- Allelic: Blood group, Ii (GCNT2)
- Allelic: Brain small vessel disease 2 (COL4A2)
- Allelic: Brain small vessel disease with/-out ocular anomalies (COL4A1)
- Allelic: Branchiootic syndrome 1 (EYA1)
- Allelic: Cardiomyopathy, dilated, 1II (CRYAB)
- Allelic: Coloboma, ocular (PAX6)
- Allelic: Deafness, AD 6/14/38 (WFS1)
- Allelic: Diabetes mellitus, noninsulin-dependent, association with (WFS1)
- Allelic: Foveal hypoplasia 1 (PAX6)
- Allelic: Hemorrhage, intracerebral, susceptibility to (COL4A1, COL4A2)
- Allelic: Hypotrichosis 14 (LSS)
- Allelic: Keratitis (PAX6)
- Allelic: L-ferritin deficiency, dominant + recessive (FTL)
- Allelic: Microangiopathy + leukoencephalopathy, pontine, AD (COL4A1)
- Allelic: Morning glory disc anomaly (PAX6)
- Allelic: Myofibrillar myopathy 11 (UNC45B)
- Allelic: Myopathy, myofibrillar, 2 (CRAB)
- Allelic: Myopathy, myofibrillar, fatal infantile hypertonic, alpha-B crystallin-related (CRYAB)
- Allelic: Neurodegeneration with brain iron accumulation 3 (FTL)
- Allelic: Optic nerve hypoplasia (PAX6)
- Allelic: Otofaciocervical syndrome (EYA1)
- Allelic: Retinal arteries, tortuosity of (COL4A1)
- Allelic: Rhizomelic chondrodysplasia punctata, type 1 (PEX7)
- Anterior segment anomalies with/-out cataract (EYA1)
- Anterior segment dysgenesis 1, multiple subtypes (PITX3)
- Anterior segment dysgenesis 2, multiple subtypes (FOXE3)
- Anterior segment dysgenesis 5, multiple subtypes (PAX6)
- Branchiootorenal syndrome 1, with/-out cataracts (EYA1)
- CODAS syndrome [Cerebral, Ocular, Dental, Auricular, Skeletal anomalies s.] (LONP1)
- Cataract 1, multiple types (GJA8)
- Cataract 10, multiple types (CRYBA1)
- Cataract 11, multiple types (PITX3)
- Cataract 11, syndromic, AR (PITX3)
- Cataract 12, multiple types (BFSP2)
- Cataract 13 with adult i phenotype (GCNT2)
- Cataract 14, multiple types (GJA3)
- Cataract 15, multiple types (MIP)
- Cataract 16, multiple types (CRYAB)
- Cataract 17, multiple types (CRYBB1)
- Cataract 18, AR (FYCO1)
- Cataract 19, multiple types (LIM2)
- Cataract 2, multiple types (CRYGC)
- Cataract 20, multiple types (CRYGS)
- Cataract 21, multiple types (MAF)
- Cataract 22 (CRYBB3)
- Cataract 23 (CRYBA4)
- Cataract 3, multiple types (CRYBB2)
- Cataract 30, pulverulent (VIM)
- Cataract 31, multiple types (CHMP4B)
- Cataract 33, multiple types (BFSP1)
- Cataract 34, multiple types (FOXE3)
- Cataract 36 (TDRD7)
- Cataract 38, AR (AGK)
- Cataract 39, multiple types, AD (CRYGB)
- Cataract 4, multiple types (CRYGD)
- Cataract 40, XL (NHS)
- Cataract 41 (WFS1)
- Cataract 42 (CRYBA2)
- Cataract 43 (UNC45B)
- Cataract 44 (LSS)
- Cataract 45 (SIPA1L3)
- Cataract 47, juvenile, with microcornea (SLC16A12)
- Cataract 48 (DNMBP)
- Cataract 49 (PANK4)
- Cataract 5, multiple types (HSF4)
- Cataract 6, multiple types (EPHA2)
- Cataract 9, multiple types (CRYAA)
- Cataract with late-onset corneal dystrophy (PAX6)
- Cataract, AR, due to abnormal sterol metabolism [panelapp] (CYP51A1)
- Cerebrotendinous xanthomatosis (CYP27A1)
- Congenital cataracts, facial dysmorphism + neuropathy (CTDP1)
- Deafness, cataract, impaired intellectual development + polyneuropathy (PSMC3)
- Galactokinase deficiency with cataracts (GALK1)
- Generalized hypotonia, developmental delay, ID, seizures, autistic behavior [panelapp] (TRPM3)
- Hemochromatosis, type 4 (SLC40A1)
- Hyperferritinemia-cataract syndrome (FTL)
- Insulinomatosis + diabetes mellitus (MAFA)
- Isolated paediatric cataract [panelapp; MONDO:0005129] (PGRMC1)
- Marinesco-Sjogren syndrome (SIL1)
- Nance-Horan syndrome (NHS)
- Neurofibromatosis, type 2 (NF2)
- Peroxisome biogenesis disorder 14B (PEX11B)
- Peroxisome biogenesis disorder 9B (PEX7)
- Sengers syndrome (AGK)
- Stickler syndrome, type I, nonsyndromic ocular (COL2A1)
- Wolfram syndrome 1 (WFS1)
- Wolfram-like syndrome, AD (WFS1)
- AD
- AR
- XL
- Multiple OMIM-Ps
Bioinformatics and clinical interpretation
Test-Stärken
- DAkkS-akkreditiertes Labor
- EU-Richtlinie für IVD in Umsetzung
- Qualitäts-kontrolliert arbeitendes Personal
- Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
- Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
- eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
- unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
- unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
- unsere umfassenden klinischen Aussagen
Testeinschränkungen
- Gene mit eingeschränkter Abdeckung werden gekennzeichnet
- Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
- es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
- die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
- Gen-Konversionen
- komplexe Inversionen
- Balancierte Translokationen
- Mitochondriale Varianten
- Repeat-Expansionen, sofern nicht anders dokumentiert
- nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
- niedriger Mosaik-Status
- Repeat-Blöcke von Mononukleotiden
- Indels >50bp (Insertionen-Deletionen)
- Deletionen oder Duplikationen einzelner Exons
- Varianten innerhalb von Pseudogenen
- die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde
Laboratory requirement
Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.
Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.
Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.
Die Untersuchung wird auch für Selbstzahler angeboten.